相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Association of GSTT1/GSTM1 and ApoE variants with left ventricular diastolic dysfunction in thalassaemia major patients
Mable Misha Singh et al.
HEMATOLOGY (2019)
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity
Elizabeth A. M. Feijen et al.
JAMA ONCOLOGY (2019)
Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics
Maria Santos et al.
GENETICS IN MEDICINE (2018)
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Bryan P. Schneider et al.
CLINICAL CANCER RESEARCH (2017)
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis
Siew Lian Leong et al.
SCIENTIFIC REPORTS (2017)
Glutathione S-transferase gene polymorphism: Relation to cardiac iron overload in Egyptian patients with Beta Thalassemia Major
Galila M. Mokhtar et al.
HEMATOLOGY (2016)
Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia
M. Krajinovic et al.
PHARMACOGENOMICS JOURNAL (2016)
CELF4 Variant and Anthracycline-Related Cardiomyopathy: A Children's Oncology Group Genome-Wide Association Study
Xuexia Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity
Paul W. Burridge et al.
NATURE MEDICINE (2016)
Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer
Gregory T. Armstrong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines
Daniel L. Hertz et al.
PHARMACOGENOMICS (2016)
Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?
Tarek Magdy et al.
PHARMACOLOGY & THERAPEUTICS (2016)
A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer
Folefac Aminkeng et al.
NATURE GENETICS (2015)
Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20+ B-cell lymphoma
Annegret Reichwagen et al.
PHARMACOGENOMICS (2015)
Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children
Henk Visscher et al.
PHARMACOGENOMICS (2015)
Hyaluronan Synthase 3 Variant and Anthracycline-Related Cardiomyopathy: A Report From the Children's Oncology
Xuexia Wang et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy
Marijke Wasielewski et al.
OPEN HEART (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation
Saro H. Armenian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Impact of Hemochromatosis Gene Mutations on Cardiac Status in Doxorubicin-Treated Survivors of Childhood High-Risk Leukemia
Steven E. Lipshultz et al.
CANCER (2013)
The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote
Yang Liao et al.
NUCLEIC ACIDS RESEARCH (2013)
Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children
H. Visscher et al.
PEDIATRIC BLOOD & CANCER (2013)
A discovery study of daunorubicin induced cardiotoxicity in a sample of acute myeloid leukemia patients prioritizes P450 oxidoreductase polymorphisms as a potential risk factor
Joanna M. Lubieniecka et al.
Frontiers in Genetics (2013)
Role of the renin-angiotensin-aldosterone system and the glutathione S-transferase Mu, Pi and Theta gene polymorphisms in cardiotoxicity after anthracycline chemotherapy for breast carcinoma
Daniela Vivenza et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS (2013)
ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia
Agnes F. Semsei et al.
CELL BIOLOGY INTERNATIONAL (2012)
Anthracycline-Related Cardiomyopathy After Childhood Cancer: Role of Polymorphisms in Carbonyl Reductase Genes-A Report From the Children's Oncology Group
Javier G. Blanco et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Role of Genetic Susceptibility in Development of Treatment-Related Adverse Outcomes in Cancer Survivors
Smita Bhatia
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2011)
Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
Maria Volkova et al.
CURRENT CARDIOLOGY REVIEWS (2011)
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21
D. Rossi et al.
LEUKEMIA (2009)
Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood
Vladan Rajić et al.
LEUKEMIA & LYMPHOMA (2009)
Using GWAS Data to Identify Copy Number Variants Contributing to Common Complex Diseases
Sebastian Zoellner et al.
STATISTICAL SCIENCE (2009)
Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort
Daniel A. Mulrooney et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:Quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer
Javier G. Blanco et al.
CANCER (2008)
Glutathione S-transferase (GSTM1, GSTT1 and GSTA1) polymorphisms and outcomes after treatment for acute myeloid leukemia:: pharmacogenetics in Southwest Oncology Group (SWOG) clinical trials
J. R. Weiss et al.
LEUKEMIA (2006)
Chronic health conditions in adult survivors of childhood cancer
Kevin C. Oeffinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Common deletion polymorphisms in the human genome
SA McCarroll et al.
NATURE GENETICS (2006)
NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity
L Wojnowski et al.
CIRCULATION (2005)
Risk of morbidity and mortality from cardiovascular disease following radiotherapy for childhood cancer: A systematic review
HJH van der Pal et al.
CANCER TREATMENT REVIEWS (2005)
Functional significance of a natural allelic variant of human carbonyl reductase 3 (CBR3)
SS Lakhman et al.
DRUG METABOLISM AND DISPOSITION (2005)
Quantitative real-time PCR for gene dosage determinations in microdeletion genotypes
J Covault et al.
BIOTECHNIQUES (2003)
Congestive heart failure in patients treated with doxorubicin - A retrospective analysis of three trials
SM Swain et al.
CANCER (2003)
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy.
GM Felker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
